Understanding the Inflation Reduction Act of 2022
Navitus’ Vice President of Government Relations, Robyn Crosson, shares her insight into the Inflation Reduction Act and how it will impact our...
Key Findings: 2021 Navitus Drug Trend Report
This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.
Employee Spotlight: Dr. Julie Olson
In a new series of spotlight posts featuring our employees, we sat down with Dr. Julie Olson to hear about her recent promotion to vice president of...
What You Need to Know About Fraud, Waste and Abuse in The Age of COVID-19
Carrie Aiken, Navitus’ Vice President of Corporate Compliance and Chief Compliance Officer, shares her perspective on how PBMs can help plan sponsors...
Building Specialty Pharmacy Success
Sharon Faust, PharmD, Vice President of Specialty Pharmacy for Lumicera shares a few key initiatives that will continue to create an impact for...
Know Your Options for At-Home COVID-19 Test Kits
As a member, plan sponsor or consultant, do you understand what the new federal guidance on free at-home COVID-19 tests means to you? As part of...
[Webinar Recap] What You Need to Know About Preventing Fraud, Waste & Abuse
Know everything you need to know about protecting your organization from pharmacy benefit fraud, waste and abuse? Chances are you don't - that's why...
Using PMPM to Measure True Bottom Line Costs
Comparing one PBM to another is very complex. To add to it, many metrics are available to help you understand if you’re getting a good deal or not....
2022 Pharmacy Benefit Predictions: What Plan Sponsors Should Watch
Navitus’ CEO, David Fields, shares his insights into the pharmacy benefits industry that will help plan sponsors achieve greater cost savings,...
[Webinar Recap] An Evidence-Based Approach to Population Health
Plans can leverage population health management programs to achieve better health outcomes. Learn a few best practices in today’s blog.
In the Pipeline: Specialty Drugs to Watch in 2022
Specialty medication development has grown rapidly, encompassing up to 80% of new FDA drug approvals in recent years. Read on to learn about the most...
In the Pipeline: Non-Specialty Drugs to Watch in 2022
Our pharmacists are always monitoring the drug development pipeline to help plan sponsors stay ahead of the curve on new and upcoming medications....
